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Pathological examination of the placenta is not universally performed and has not received as much general interest as many other areas of surgical pathology. This is in response to many factors, one of which is the misconception that the relevance of pathologic diagnoses in the placenta is of lesser importance than that of other subspecialties. We hope that in this review we can educate both the general surgical pathologist and the obstetrical care provider of the utility of placental pathologic examination, focusing on three diagnoses with significant clinical relevance. Of the myriad of placental pathologic findings with clinical implications, those with recurrence risks are especially important for families and for providers. There are just a handful of such lesions, and they remain biologic curiosities without specific known etiologies. These lesions, villitis of unknown etiology, chronic histiocytic intervillositis/massive chronic intervillositis, and massive perivillous fibrin deposition/maternal floor infarct, have in addition to their predisposition to recur in subsequent pregnancies, significant associated increase in perinatal morbidity and mortality. In this review, we discuss these entities with a focus on the pathologic criteria for the diagnosis and the associated clinical relevance. Many excellent reviews for these three pathologic diagnoses have been published recently, and we encourage the readers to access them for further study [e.g., (1) (2) (3) (4) ].
VILLITIS OF UNKNOWN ETIOLOGY
Chronic villitis is a relatively common pathologic finding usually in the third trimester placenta and has two distinct clinical associations: infectious and (apparently) non-infectious. Villitis of unknown etiology (VUE) is a diagnosis of exclusion, requiring first that infectious causes be ruled out adequately (1, (4) (5) (6) (7) (8) (9) (10) (11) . VUE is far more common than its infectious counterpart (1, 10, (12) (13) (14) (15) (16) (17) and the two present differently: in cases of the latter, usually there are signs and symptoms of infection in the mother or fetus/neonate (1) . Infectious causes of villitis also are suspected at earlier gestational ages (1) . VUE is defined histologically as significant chorionic villous mononuclear inflammation comprised of some combination of lymphocytes and histiocytes, with or without villous necrosis or sclerosis (Fig. 1A) (11, 16) . It was described in 1961 by Gershon and Strauss as part of a misleadingly termed 'placental insufficiency syndrome' associated with intrauterine growth restriction (IUGR) (18) . Since then, many more studies have examined its epidemiology, clinical associations, and immunobiology. Some of these studies well document its recurrence risk (see for example [3] and [8] ).
VUE affects 6.6-33.8% of third trimester, predominantly term placentas (4, 16) , with its reported incidence dependent on placental sampling, diagnostic criteria, and locoregional population characteristics (10, 13, 14) . As only a subset of placentas undergo pathologic evaluation for maternal, fetal, or obstetrical indications, its true incidence is difficult to ascertain. It is believed that approximately 60% of VUE cases are detected with placental , is commonly seen alongside basal villitis although not always (H&E). (E) and (F) Lymphoplasmacytic villitis secondary to CMV infection. In this case, as in many cases, the placenta was large for gestational age. Sections of sampled parenchyma show slightly immature villi diffusely involved by a lymphoplasmacytic infiltrate. When presented with this low-power appearance (E), one must be on the lookout for other, more specific features of CMV villitis, such as hemosiderin deposition (F) and intranuclear viral inclusions (not shown) (H&E).
parenchyma sampling in three blocks (11) , and the detection rate increases with more robust pathologic sampling. Altemani et al. showed that 6 blocks are needed to detect 85-95% of cases (19) . Khong et al. reports a subjective component to the diagnosis in an intra-and interobserver variability study (20) which should be diminished with stricter diagnostic criteria as in that put forth by the Amsterdam Placental Workshop Group (11) . VUE is a light microscopic diagnosis, characterized by an intravillous lymphohistiocytic cellular infiltrate (11, 16) . The majority of the inflammatory cells are within the substance of the villous stroma, but there may be spillage of inflammation into the intervillous space (1), often with associated increased perivillous fibrin deposition (12, 13) . When intervillous inflammation is marked, the differential diagnosis of chronic histiocytic intervillositis (1) or a combined lesion (3) must be considered. Often, gross lesions are not described in cases of histologic VUE (14) , but findings have been noted such as firmness and, in severe cases, parenchymal necrosis leading to mottling (15) . The placenta often is small, particularly when there is associated IUGR (15) . VUE should be classified as low grade or high grade (11) . Low-grade VUE is defined as two or more foci of lymphohistiocytic villitis affecting fewer than 10 contiguous villi. High-grade cases demonstrate multiple foci in more than one slide with the villitis affecting more than 10 contiguous villi (11) . The distribution of VUE is variable, showing one of three patterns: (1) proximal, involving stem villi (Fig. 1B) , (2) distal, involving intermediate and terminal villi (Fig. 1C) , and (3) basal, involving the anchoring villi and adjacent terminal villi ( Fig. 1D) (1) . The proximal form is commonly seen with fetal vascular malperfusion, such as vascular thrombosis with or without downstream villous stromal-vascular karyorrhexis and avascular villi (1, 6, 12, 17, 21) . Plasma cell deciduitis is commonly encountered in cases of basal VUE (1, 12, 22, 23) .
Some of the early papers on VUE separated lymphocyte-predominant and histiocyte-predominant forms, but these studies failed to show significantly different clinical outcomes in liveborn infants (12) (13) (14) . These older reports additionally described uncommon cells that may be seen in VUE: plasma cells and multinucleated histiocytes (non-syncytiotrophoblast giant cells) (12, 13) . Villous plasma cells raise suspicion for an infectious villitis, and the pathologist must be alert to other infection-associated pathologies such as villous stromal hemosiderin deposition and (certainly) viral inclusions as in CMV or HSV placentitis (Fig. 1E ) (1, 11, 17) . Giant cells in a specific clinical context may raise suspicion for Toxoplasma gondii or Trypanosoma cruzi infection (1) . Overt granulomatous villitis is not part of the VUE spectrum and suggests mycobacterial or fungal infection (1) . Generally, however, the morphologic findings of VUE differ enough from those of infectious villitis to allow for a specific diagnosis of one or the other. The former is typically less diffuse than the latter, which frequently involves the cord, membranes, and chorionic plate (1) .
In their large series of VUE, Redline and Abramowsky noted two 'flavors' of VUE; one affected younger, unmarried women of lower socioeconomic status and with a history of sexually transmitted infections and was often basal with associated plasma cell deciduitis, whereas the other affected older women who were of higher socioeconomic status, frequently overweight or obese, with a history of multiple spontaneous abortions and was often more diffuse with prominent intervillous fibrin or intervillositis (23) . Further studies have revealed associations between VUE and maternal factors such as hypertensive disorders including preeclampsia (6, 13, 24, 25) , autoimmune disease such as systemic lupus erythematous and autoimmune thyroid disease (23, 26, 27) , overweight/obesity (23, 25) and history of recurrent losses including intrauterine fetal demise (IUFD) and neonatal death (5, 13, 22, 23, 25) . While the most common outcome of VUE is delivery of a healthy infant, the most common clinical condition associated with VUE is IUGR (3, 22, (28) (29) (30) . VUE has been associated with many fetal/neonatal morbidities including abnormal cord flow by Doppler ultrasound (3, 29, 30) , abnormal cord blood gases indicative of hypoxia (31), perinatal mortality (3, 5, 23, 30, 32) , neonatal intensive care unit (NICU) admission (3, 5) , neonatal seizures (3), and neonatal encephalopathy and cerebral palsy (CP) (21, 33) . VUE is more common at term; however, it is certainly diagnosed in preterm placentas (6, 30, 34) .
The cause of VUE is unknown although it has been recognized since the 1960s and 1970s. There are two major proposed etiologies: (1) A hitherto unrecognized infectious agent or (2) a graft-vs-host disease-like immune rejection phenomenon (1, 4, 10, 35) . The literature has many examples of cases diagnosed as VUE later found to be infectious in origin. For example, in 1999, Benirschke et al. reported two cases of misdiagnosed VUE in which Varicella and Toxoplasma were later identified (36) . Clinical suspicion of infection led to further workup in these cases; thus, they really do not meet the criterion of VUE that infection be ruled out sufficiently first. Further inquiry into the potential for an infectious etiology has yet to finger a specific agent or agents. While viral-like particles detected by electron microscopy were noted in some placentas with VUE (37), these particles were not seen in all of the cases, nor were normal placental controls reported (1, 38) . Ernst et al. did not detect bacterial 16S ribosomal RNA in placentas with VUE using PCR (7). Cajaiba et al. considered the possibility of human polyomavirus BK as a cause, but their ISH studies were negative (9) . Despite this, we cannot completely exclude the possibility that many cases of VUE are actually infectious in etiology with the specific organism not currently identifiable.
There are many clinical features of VUE that suggest an immune component to the etiology. In fact, support for the immune rejection hypothesis has grown in recent years. VUE is seen with increased frequency in cases of maternal autoimmune disease (23, 26, 27) and pregnancies complicated by neonatal alloimmune thrombocytopenia (39) . The fetus is essentially an hemiallogeneic graft, and successful pregnancy requires a shift from maternal Th1 (cellular immunity) to Th2 (humoral immunity) responses (38, 40, 41) , which includes an alteration in cytokine profile from predominantly IL-2, IL-6, and IL-12 to anti-inflammatory IL-4, IL-10, and TGF-b (41). Derricott et al. found abnormally increased IL-2 and IL-12 in VUE lesions in placentas associated with stillbirth (41), suggesting inappropriately activated cellular immunity.
Both lymphocytes and macrophages cells participate in VUE (42) (43) (44) (45) , the former consisting of mostly maternal CD8+ > CD4+T cells (45, 46) and the latter a mix of predominantly maternally derived macrophages in the intervillous space and fetal Hofbauer cells in the villous proper (45, 47) . Both Class I and Class II MHC antigens are absent from normal syncytiotrophoblast (40) , but in VUE lesions, segments of syncytiotrophoblast membrane react to antibodies against Class II antigens (48, 49), including HLA-DR, HLA-DP, and HLA-DQ (42) , which may be the result of cytokine signaling by activated fetal macrophages (42, 50) . Abnormally increased intercellular adhesion molecule 1 (ICAM-1) expression has been described on syncytiotrophoblast (50, 51) , which would facilitate traffic of maternal immune cells into villi, but the reason for such upregulation is unclear. Maternal rejection of the fetoplacental unit also is supported observations such as increased rates of VUE when in vitro fertilization pregnancies utilize donor rather than native oocytes (52, 53) . A report of asymmetrical involvement of placental disks from monozygotic twins by VUE is mystifying (53) but obviously would be unexpected for an infectious etiology as well. Increased rather than decreased maternal CD25 + FOXP3 + regulatory T cells in VUE lesions is also puzzling (54) . Although most studies have explored a cell-mediated mechanism behind VUE, the role for a humoral component to VUE is posited by a C4d immunohistochemical study finding syncytiotrophoblast staining in VUE lesions much above controls (55) .
The recurrence risk of VUE is estimated in the 10-15% range (1), but individual reports have shown rates as high as 37% (8), though such high rates are with small cohorts and limited by the fact that often placental examination is performed only when there is a clinical (maternal, fetal, or obstetric) indication. We have found a rate similar to Redline's 10% (1) in our practice (data not shown). Recurrent VUE seems to be more associated with maternal autoimmune disease (23, 26, 27) and history of recurrent losses, especially in the third trimester (8, 23, 32) . Redline and Abramowsky found that their recurrent VUE cohort had more workup for autoimmunity than did their control cohort, with autoimmune disease diagnosed in 5/6 recurrent VUE patients compared with 0/1 control group patients (23) . When it recurs, VUE again is strongly associated with IUGR/SGA (23, 24, 32) , IUFD, and neonatal death (8, 23, 32) . We recommend that whenever a diagnosis of VUE is entertained, review of previous obstetric pathologies ensue to evaluate for recurrence due to these associated morbidities with recurrent VUE. A diagnosis of recurrent VUE should be notified to the clinician as a critical result.
In his review on VUE, Boog mentions the empiric treatment of pregnant women with recurrent VUE with a combination of prednisone, which does not cross the placental barrier, and low-dose aspirin from 12 to 35 weeks gestation, with overall good result, although one IUFD occurred at 16 weeks gestational age, with placental pathology demonstrating severe chronic intervillositis (10, 56) . Another proposed regimen is weekly IVIG. Althaus et al. reported that when mothers with pregnancies affected by neonatal alloimmune thrombocytopenia were treated with weekly IVIG, their placentas were negative for VUE, compared to placentas with VUE from mothers who went untreated (39) . This result also supports a contribution of humoral immunity to VUE.
VUE is a fairly common placental histologic diagnosis that can be both easily missed and over diagnosed. High-grade lesions are of clinical importance, as many studies have associated high-grade VUE with suboptimal fetal/neonatal outcomes, including IUGR/SGA, neurologic complications, such as CP, and stillbirth or neonatal death. The cause of VUE yet remains enigmatic, but the preponderance of evidence points toward a host-vsgraft-disease-like immunologic phenomenon with a to-be-determined mechanism. It is believed to have a modest recurrence risk, perhaps elevated in women with autoimmune disease and history of recurrent pregnancy losses.
CHRONIC HISTIOCYTIC INTERVILLOSITIS
In 1987, Labarrere and Mullen (57) described an entity they referred to as 'an extreme variant of villitis of unknown etiology' evidenced by marked intervillous inflammation, intervillous fibrin, and trophoblast necrosis. The original report describes the lesion occasionally accompanied by VUE. The inflammatory cells have been immunophenotyped to be predominately histiocytes. This has since been termed chronic histiocytic intervillositis (CHI), also known as massive chronic intervillositis or chronic intervillositis of unknown etiology. The lesion is important due to its high recurrence rate from approximately 70% (58) to 100% (59) and its association with significant fetal morbidity and mortality (see below).
The prevalence of CHI is not precisely known, but reports have suggested it is quite rare ranging from approximately 1 to 10 per 1000 gestations depending on gestational age (58, 59) or <1% of all pregnancies (50, 60, 61) . It is a pathology that can present at any gestational age but appears to be more common in early gestations (58) . There seems to be no strong predisposing factors other than a history of pregnancy losses, but CHI has been reported in primigravidas (60) . It does not appear to be increased in prevalence by maternal age. It may be more common with maternal autoimmune disorders (58, 62, 63) , with approximately 6% prevalence in CHI cases (60) . One report found 2 of 4 cases in pregnancies from assisted reproduction (61) . There is also a hint of increased thrombophilia in mothers with CHI affected pregnancies (60) .
Clinically, CHI has been associated with a significant increase in spontaneous abortions, perinatal morbidity, and IUFD (3, (58) (59) (60) 64) . Perinatal morbidity reported includes a high rate of severe intrauterine growth restriction (IUGR) present in 66% (60) to more than 80% (3) of cases. Preterm delivery is also common, many indicated due to severe IUGR (56, 58, 60, 62, 65, 66) . Fetal disorders have also been noted including several cases associated with neonatal alloimmune thrombocytopenia (NAIT) (67, 68) , a few cases of chromosomally or syndromically anomalous fetuses (58, 63) and a single case of recurrent CHI described with fetal skeletal anomalies mimicking osteogenesis imperfecta (69 Mothers with gestations affected by CHI often have elevated maternal serum alpha-fetal protein (msAFP) (58) or alkaline phosphatase (AlkPhos) (60) , useful markers to diagnose recurrence with subsequent pregnancies. Marchaudon et al. (60) noted that the pregnancies complicated with high AlkPhos (>2.5 9 normal levels) had a higher prevalence of severe IUGR (80%). Oligohydramnios has also been noted in cases complicated with IUGR (59). Even with live birth, most infants are growth restricted and many will die in the perinatal period [only 32% of the babies lived more than 1 week in the study of Rota et al. (63)]. The clinical diagnosis can be suggested with a maternal history of a previous affected pregnancy, early onset and severe IUGR, and potentially elevated serum markers. Due to the high incidence of some type of poor outcome many clinicians opt for early delivery or early treatment with immunosuppressive or antithrombotic therapy (56, 62, 65, 70) .
There have been no descriptions of gross placental pathology in CHI. The diagnosis is made microscopically by histology of the placental tissues. The diagnosis can also be made by reviewing histology of chorionic villous sampling in the first trimester (63) . CHI is characterized by maternal space/intervillous space filled with an admixture of predominantly histiocytes with a smaller collection of lymphocytes often with admixed fibrin/fibrinoid material ( Fig. 2A) . Villous trophoblast necrosis is also present to varying degrees. Decidual atherosis has been noted in association with some cases (50, 57) . CHI is usually marked and diffuse but has been diagnosed even with more limited placental involvement (59, 60) . Some have noted that complications follow the severity of the CHI (3, 59, 63), but others have found the opposite -that less severe or diffuse CHI is associated with a higher rate of IUFD (60) . We have noticed that in early gestations, the involvement is generally limited (Fig. 2B) and is often only 'picked up' upon review after a recurrence (65, 70) . Early cases often have a more conspicuous fibrin component (60) . Immunohistochemistry can highlight the histiocytes, a CD68 stain is confirmatory (Fig. 2C, D) . Heller (71) has defined the range of CD68 positive cells in normal vs CHI cases, useful especially for the less severe cases. Immunophenotyping of the cellular infiltrate reveals mainly CD68 + histiocytes with few CD8 > CD4 + T cells. Most of the cells are ICAM-1+ (50) . Accompanying VUE occurs in approximately 25-35% of cases (3, 59, 63) . When present, the VUE should be a lesser component of the pathology that the CHI. One manuscript describes the clinical implications of CHI with VUE and finds that these cases 'behave' more like VUE than CHI (3). Whether or not they are mutually exclusive is controversial. We have made the diagnosis of CHI with VUE but only rarely. There is evidence that they represent a spectrum of the same disorder (50) .
A small subset of CHI cases are infectious in etiology, most notably due to malarial sequestration (72) . One study found an infectious component in 21% of their CHI cases (63) . A large number of infections may have an intervillositis component and can be suspected based on the clinical history and the composition of the infiltrate. CHI should be primarily histiocytes with lymphocytes. Intervillositis with a mixed inflammatory infiltrate are often seen in association with high-grade acute or chronic villitis, or with abscesses, and these cases should be evaluated for an infectious cause. Placental infections that have been described with a prominent intervillositis include Chlamydia psittaci (73), CMV (74), Listeria monocytogenes, tularemia, coccidioidomycosis, rickettsiosis, blastomycosis, schistosomiasis (58) (59) (60) and Zika virus (75) .
Most CHIs are apparently non-infectious, and the etiology of non-infectious CHI is unclear.
The inflammatory cells are maternal (61) and the recurrence rate is high, both suggesting that there is an immunological basis for the pathology. Many have suggested it is a host-vs-graft like phenomenon (50, 57, 58, 60, 61, 76) like that described above for VUE. Additional support for this theory is the association with maternal autoimmune disorders (58, 60, 62) . Some have found markers supportive of rejection-like pathology with C4d immunolocalized to the syncytiotrophoblast in CHI (77) and the presence of maternal auto-antibodies (62) . But there is other evidence that refutes this rejection pathology hypothesis. For example, there is a case report of monochorionic twins with discordance for CHI (78) . Others have suggested that, due to increased expression of a receptor involved in bacterial inflammatory responses (TLR1), an infectious etiology (perhaps transient) may be a more common etiology (79) . The known, albeit rare, infectious causes of CHI offer some support to this hypothesis.
The recurrence risk for CHI is very high, the highest of the three pathologies discussed herein. Recurrences have been reported to range from nearly 70% (58) to 100% (59) although was noted less frequently at 18% in one large study (60) . Recurrences often present at earlier gestational ages than the initial case (65, 70) . Treatment clearly seems to decrease recurrence and some complications. One report of 24 cases of recurrent CHI (62) in which 88% received a variety of treatments (aspirin, low-molecular-weight heparin, prednisone, hydroxychloroquine in combinations or alone and treated either before or during pregnancy) found no difference in the different treatment regimes in outcomes, but they found treatment resulted in more livebirths than no treatment (67% vs 32%, respectively). Treatment did not obviate all morbidities though, and it had no effect on the incidence of premature delivery (although they did not comment on if these deliveries were spontaneous or indicated). Recurrent CHI, history of complicated CHI (with IUGR or IUFD), and no treatment appear to be risk factors for poor outcome (IUGR or IUFD).
We suggest that when a diagnosis of CHI is entertained, review of previous perinatal pathologies should ensue. Examination of the clinical record for any suggestion of a possible infectious etiology is necessary as well. Due to its significant clinical implications, this diagnosis should be reported promptly to both the obstetrician and the pediatrician. Evaluation of the mother for autoimmune disorders and thrombophilias is encouraged and consultation with a maternal-fetal medicine specialist is needed for future pregnancies. Neonatal observation for NAIT and neurocompromise is suggested.
The pathological diagnosis of CHI is poorly recognized by the general pathologist. It remains one of the most important pathological diagnoses in spontaneous abortions and in IUFDs due both for its significant recurrence risk and for its maternal and fetal clinical implications. It also provides the etiology of the loss as placental. Understanding the biology of this lesion will aid in the development of appropriate treatment and early diagnosis of CHI, and likely provide insight into the immunoregulatory aspects of normal pregnancy.
MASSIVE PERIVILLOUS FIBRIN DEPOSITION/MATERNAL FLOOR INFARCT
The presence of focally increased perivillous or intervillous fibrin/fibrinoid is a relatively common finding in third trimester placentas, less so in earlier gestations. Its relevance is related to many factors, including its quantity (how much perivillous fibrin there is), the placental size (small placentas may be compromised with a smaller volume of fibrin), and the gestational age (term placentas often have benign fibrin at the margins). Increased perivillous fibrin may be due to turbulence and slow flow especially at placental margins or immediately under the chorionic plate. Pathologic increased perivillous fibrin is postulated to be a reaction to trophoblastic damage/necrosis resulting in villous stroma exposure to the maternal space stimulating the clotting cascade and is thus associated with placental pathologies that are characterized by trophoblastic damage (e.g., diabetic pregnancies) (80) . In rare cases, the perivillous fibrin is so increased that it obstructs maternal flow in a significant portion of the placenta with fetal consequences. This has been termed 'massive perivillous fibrin deposition' (MPFD) also known as 'maternal floor infarct' (MFI). This entity was first described in seminal works by Benirschke in 1961 (81) and in 1967 by Benirschke and Driscoll (82) who described the lesion as a 'diffuse thickening of the maternal floor of the placenta, which is rendered pale, either white, gray or yellow, and smoother than normal'. It has been shown that the restriction of the fibrin to the maternal floor is not universal and often 'the placental substance contains increased quantities of fibrin. . .through the placental amnion' (82) . Since the original descriptions in the 1960s, MPFD/MFI has received a lot of attention due to its association with perinatal morbidity and mortality and its significant recurrence risk.
MPFD/MFI is a rare lesion, reported in <1% of all pregnancies (83) (84) (85) (86) . Its clinical significance involves many fetal and neonatal morbidities including severe IUGR (87-89), preterm birth (PTB) (85), cystic renal dysplasia (90) , hypercoiled umbilical cord with single umbilical artery (91), renal tubular dysplasia (92) , fetal metabolic disease with reported mutations in the LCHAD (long-chain 3-hydroxyacyl-CoA-dehydrogenase) gene (93, 94) , and oligohydramnios (90, 95) . Neonatal morbidities include an association with neurocompromise (87, 96) . The stillbirth rate is reported to be very high at 13-50% (85, 86, 95) . There is also an increased neonatal mortality rate, likely from complications of PTB, metabolic disease, and IUGR. The recurrence rate has been reported to range from 12 to 78% (84) (85) (86) (96) (97) (98) . Our experience is near the mid-range, less than we have seen with CHI but more than that with VUE. As with CHI, MPFD/MFI when it recurs tends to recur earlier in gestation.
The gross findings of MPFD/MFI are as expected for increased fibrin/fibrinoid with global or a significant regional deposition. The placenta is pale and firm (Fig. 3A) as the increased fibrin/fibrinoid present is often marbled, streaky, or diffuse. Benign increase in perivillous fibrin/fibrinoid is typically nodular or mass-like and focal on cut section (Fig. 3B) . The increased density of the placenta from the fibrin can be diagnosed by sonography (99, 100) . The gross findings are critically important as knowing the percent placental involvement is necessary to make or rule-out the diagnosis (97) . At least 25% of the placenta must be involved, whether that is only the maternal floor (for classic MFI) or the parenchyma (for MPFD) to confirm the diagnosis. Smaller foci of fibrin are common at term and should be sampled, but if <25% of the placental mass they should not be interpreted as MFI/MPFD. It is prudent to amply sample the placenta in affected regions and grossly unaffected regions, making note of the estimated percent involvement in the gross description. We make the diagnosis only when at least 25% of the placenta is grossly involved (whether basally only or transmurally) and is histologically verified.
Histology of this lesion is characterized by abundant fibrin/fibrinoid material speckled through the inter/perivillous space appearing to suffocate the villi (Fig. 3C) . Often, there is syncytiotrophoblastic necrosis of the entrapped villi (Fig. 3C) . Proliferation of septal/chorionic extravillous trophoblast within the fibrin can be striking (Fig. 3D) . The amount of fibrin/ fibrinoid must be significant (especially if the percent involvement was not noted on gross examination) with the admission that this is subjective and semiquantitative (97) . Drs. Faye-Petersen and Ernst summarized and categorized the diagnostic criteria nicely in their 2013 manuscript (2) as:
1. Classic: basal villous encasement by fibrinoid along the entire maternal floor and of 3 mm or greater in thickness on at least one slide 2. Borderline: involvement of 25-50% of the villi on at least one slide in a transmural (basal to chorionic plate) distribution. 3. Transmural MPFD: transmural perivillous involvement with encasement of ≥50% of the villi on at least one slide.
These categories and criteria work well for late second and third trimester cases in which an intact placenta is available for examination. In first trimester and early second trimester cases, when typically the surgical pathologist has only fragments of placental tissue often mixed with decidua, these criteria cannot be reliably applied. In such cases, the gross findings are not usually evident and the diagnosis is based predominantly on histology. Less involvement (more limited or focal fibrin/fibrinoid) is typical. We believe in this early gestational time period inter/perivillous fibrin/fibrinoid is always pathologic, with only two caveats in the differential diagnosis. Medically induced abortions often have abundant inter/perivillous fibrin and the diagnosis of MFI/MPFD should be entertained only with great caution and with some confirmatory information (e.g. history of multiple losses or previous loss with MFI/MPFD). Prolonged retention of a missed abortion may also have excess inter/perivillous fibrin/fibrinoid. In the absence of these two clinical scenarios, the presence of any inter-perivillous fibrin/fibrinoid should raise the possibility of MFI/ MPFD. The amount necessary to be confident in the diagnosis is subjective. We offer no firm guidelines but suggest that more than focal presence, or with associated trophoblast necrosis, or with clinically associated findings, should support a diagnosis of MFI/MPFD in the first or second trimester. MFI/MPFD can be associated with a lesser contribution of inflammatory pathology -intervillositis or chronic villitis, but it should be a very minor component of the pathology. Anything more than focal should raise the differential diagnosis of VUE with increased perivillous fibrin/fibrinoid or CHI. We admit that some cases are very difficult to definitively differentiate. Consultation with the clinicians for complete obstetrical history should be obtained. As the diagnosis has significant ramifications for the patient, review by a perinatal pathologist may be helpful.
The etiology of MFI/MPFD is not known. Many have suggested that there is an immunological basis for the pathology (76) similar to the other pathologies described herein. The host vs placental/fetal semi-allograft hypothesis for this lesion is based on the following facts: there is a significant recurrence risk, there is an increased incidence of the lesion in women with antiphospholipid antibody syndrome (APAS) (101) and other autoimmune pathologies (88, 102) ; discordances have been reported in both monochorionic (84) and dichorionic (89) placentas; and that immunotherapy treatment seems to have a protective affect (103) (104) (105) (106) . Another theory is that maternal thrombophilia is a significant factor associated with the pathology (107) (108) (109) (110) (111) . A final theory is that these cases are due to an imbalance of angiogenic/antiangiogenic factors as measured by increased concentrations of sENG and sVEGFR-1 (112) . Due to these associations, once a diagnosis is made, the mother should be evaluated for coagulopathies and for autoimmune disorders. As in the other pathologies discussed in this review, there can be an infectious etiology with Coxsackie virus infection being reported in several cases (113) (114) (115) .
Clinical diagnosis should be suspected whenever there has been a history of multiple ante-or perinatal losses and severe early onset IUGR with oligohydramnios. Additional serum markers may be helpful and include an elevated msAFP (100, 116) , sENG, and sVEGFR-1 (112) . Treatment modalities have been reported with some success including primarily thrombolytic therapies (aspirin, heparin) with or without combining immunologically directed treatments (e.g., IVIG) (103, 105, 106) . One report notes a live birth with normal post-natal follow-up at 2 years in a woman with a history of four consecutive losses presumably all due to MFI/MPFD (one case confirmed) who was treated with a combination of thrombolytic therapy (aspirin and heparin), IVIG, and an 'innovative therapy' of a statin (pravastatin) to 'correct' her angiogenic/antiangiogenic imbalance thought to be causational of her recurrent MFI/MPFD (106) . These reports of isolated successes, but also failures, with a variety of treatments, are not without concerns (side effects and cost to name two) highlight the need for careful and definitive diagnosis and for caution in recommending therapy. There is definitely a need for further study.
Given the clinical associations, MFI/MPFD is another diagnosis we believe should be reported promptly to the obstetrician and pediatrician.
DISCUSSION/CONCLUSION
In this brief review of three placental pathologies with significant recurrence risks, we have emphasized the importance of these diagnoses not only due to their recurrence risk but also due to their significant associated fetal/neonatal and maternal morbidities and mortalities. We have encountered many sad cases of multiple perinatal losses due to one of these pathologies, and the personal grief and clinical frustration should not be underestimated. These pathologies are not well known by general surgical pathologists and we hope that this review brings appropriate attention to them. We feel that these are three diagnoses that should not be missed as they have real clinical implications and require specific studies on the mother and any surviving infant. We hope that this review highlights the utility of examining tissues from early pregnancy losses especially those with a history of a previous perinatal loss. Review of all previous obstetric pathologies is a critical part of making these diagnoses and should be a routine aspect of the pathological evaluation of all perinatal specimens.
We have brought up the frustrating fact that none of the three pathologies have a known specific etiology. Hypotheses vary for all three from undiscovered infectious etiology, immunologically based rejection-like disorder, maternal coagulopathies, and imbalance between angiogenic/antiangiogenic pathways. Perhaps, these pathologies are not 'pure' but consist of different etiologies that can include more than one specific cause. This requires focused investigation, which we encourage the scientific community to embrace.
